gatifloxacin has been researched along with Enteric Fever in 12 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever." | 9.22 | Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial. ( Adhikari, N; Arjyal, A; Baker, S; Basnyat, B; Dolecek, C; Dongol, S; Gajurel, D; Giri, A; Joshi, N; Karkey, A; Koirala, S; Lamsal, D; Lamsal, K; Mahat, SP; Merson, L; Nhan, HT; Pathak, KR; Prajapati, SP; Shah, G; Shakya, M; Shrestha, P; Thanh, DP; Thapa, R; Thieu, NTV; Thompson, CN; Thwaites, GE; Wolbers, M; Yadav, BK, 2016) |
| "Adults and children clinically diagnosed with uncomplicated enteric fever were enrolled in the study to receive gatifloxacin (10 mg/kg/day) in a single dose or ofloxacin (20 mg/kg/day) in two divided doses for 7 days." | 9.17 | Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial. ( Agrawal, K; Arjyal, A; Baker, S; Basnyat, B; Campbell, J; Dolecek, C; Dongol, S; Farrar, J; Giri, A; Karkey, A; Koirala, KD; Koirala, S; Pathak, KR; Shakya, M; Shilpakar, O; Shrestha, K; Shrestha, R; Shrestha, UM; Thapa, SD; Wolbers, M, 2013) |
| "We aimed to investigate whether gatifloxacin, a new generation and affordable fluoroquinolone, is better than chloramphenicol for the treatment of uncomplicated enteric fever in children and adults." | 9.15 | Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. ( Agrawaal, KK; Arjyal, A; Baker, S; Basnyat, B; Campbell, JI; Dolecek, C; Dongol, S; Farrar, J; Karkey, A; Khatri, NS; Koirala, S; Lama, S; Shakya, N; Sharma, M; Shrestha, K; Shrestha, U; Wolbers, M, 2011) |
| "We performed a randomised controlled trial to compare the efficacy and safety of gatifloxacin (10 mg/kg/day) versus azithromycin (20 mg/kg/day) as a once daily oral dose for 7 days for the treatment of uncomplicated typhoid fever in children and adults in Vietnam." | 9.13 | A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. ( Basnyat, B; Campbell, JI; Doan, CD; Dolecek, C; Dunstan, SJ; Duong, TL; Farrar, J; Ha, V; Le, TP; Luong, BH; Mai, NL; Nguyen, NR; Nguyen, TA; Nguyen, TB; Nguyen, TC; Nguyen, VM; Nguyen, VS; Nguyen, VV; Pham, ND; Phan, VB; Phung, QT; Schultsz, C; Stepniewska, K; To, SD; Tran, TC; Tran, TH; Tran, TP; Tran, TT; Vo, AH, 2008) |
| "To assess the efficacy of gatifloxacin versus cefixime in the treatment of uncomplicated culture positive enteric fever." | 9.12 | An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. ( Arjyal, A; Basnyat, B; Campbell, JI; Dangol, S; Day, JN; Dolecek, C; Farrar, JJ; Pandit, A; Paudyal, B; Stepniewska, K; Yadav, B; Zimmerman, MD, 2007) |
| "The epidemiology of typhoid fever in South Asia has changed." | 5.48 | Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India. ( Balaji, V; Bandyopadhyay, R; Jasmine, S; Rupali, P; Sathyendra, S; Yadav, B, 2018) |
| "Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever." | 5.22 | Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial. ( Adhikari, N; Arjyal, A; Baker, S; Basnyat, B; Dolecek, C; Dongol, S; Gajurel, D; Giri, A; Joshi, N; Karkey, A; Koirala, S; Lamsal, D; Lamsal, K; Mahat, SP; Merson, L; Nhan, HT; Pathak, KR; Prajapati, SP; Shah, G; Shakya, M; Shrestha, P; Thanh, DP; Thapa, R; Thieu, NTV; Thompson, CN; Thwaites, GE; Wolbers, M; Yadav, BK, 2016) |
| "Adults and children clinically diagnosed with uncomplicated enteric fever were enrolled in the study to receive gatifloxacin (10 mg/kg/day) in a single dose or ofloxacin (20 mg/kg/day) in two divided doses for 7 days." | 5.17 | Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial. ( Agrawal, K; Arjyal, A; Baker, S; Basnyat, B; Campbell, J; Dolecek, C; Dongol, S; Farrar, J; Giri, A; Karkey, A; Koirala, KD; Koirala, S; Pathak, KR; Shakya, M; Shilpakar, O; Shrestha, K; Shrestha, R; Shrestha, UM; Thapa, SD; Wolbers, M, 2013) |
| "We aimed to investigate whether gatifloxacin, a new generation and affordable fluoroquinolone, is better than chloramphenicol for the treatment of uncomplicated enteric fever in children and adults." | 5.15 | Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. ( Agrawaal, KK; Arjyal, A; Baker, S; Basnyat, B; Campbell, JI; Dolecek, C; Dongol, S; Farrar, J; Karkey, A; Khatri, NS; Koirala, S; Lama, S; Shakya, N; Sharma, M; Shrestha, K; Shrestha, U; Wolbers, M, 2011) |
| "We performed a randomised controlled trial to compare the efficacy and safety of gatifloxacin (10 mg/kg/day) versus azithromycin (20 mg/kg/day) as a once daily oral dose for 7 days for the treatment of uncomplicated typhoid fever in children and adults in Vietnam." | 5.13 | A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. ( Basnyat, B; Campbell, JI; Doan, CD; Dolecek, C; Dunstan, SJ; Duong, TL; Farrar, J; Ha, V; Le, TP; Luong, BH; Mai, NL; Nguyen, NR; Nguyen, TA; Nguyen, TB; Nguyen, TC; Nguyen, VM; Nguyen, VS; Nguyen, VV; Pham, ND; Phan, VB; Phung, QT; Schultsz, C; Stepniewska, K; To, SD; Tran, TC; Tran, TH; Tran, TP; Tran, TT; Vo, AH, 2008) |
| "To assess the efficacy of gatifloxacin versus cefixime in the treatment of uncomplicated culture positive enteric fever." | 5.12 | An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. ( Arjyal, A; Basnyat, B; Campbell, JI; Dangol, S; Day, JN; Dolecek, C; Farrar, JJ; Pandit, A; Paudyal, B; Stepniewska, K; Yadav, B; Zimmerman, MD, 2007) |
| "During a typhoid clinical treatment trial in Nepal, we observed several treatment failures and isolated highly fluoroquinolone-resistant Salmonella Typhi (S." | 2.82 | A novel ciprofloxacin-resistant subclade of H58 Salmonella Typhi is associated with fluoroquinolone treatment failure. ( Arjyal, A; Baker, S; Basnyat, B; Dolecek, C; Dongol, S; Dougan, G; Gajurel, D; Ha Thanh, T; Ho Thi, N; Holt, KE; Karkey, A; Parry, CM; Pham Thanh, D; Pickard, D; Pradhan, A; Rabaa, MA; Shrestha, SK; Thompson, CN; Thwaites, GE; Tran Vu Thieu, N; Voong Vinh, P; Wolbers, M; Wong, V, 2016) |
| "The epidemiology of typhoid fever in South Asia has changed." | 1.48 | Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India. ( Balaji, V; Bandyopadhyay, R; Jasmine, S; Rupali, P; Sathyendra, S; Yadav, B, 2018) |
| "We found serological evidence of acute murine typhus in 21 of 125 (17%) patients, with 12 of 21 (57%) patients polymerase chain reaction (PCR)-positive for Rickettsia typhi." | 1.42 | Undifferentiated febrile illness in Kathmandu, Nepal. ( Arjyal, A; Baker, S; Basnyat, B; Blacksell, SD; Day, N; Dolecek, C; Dongol, S; Farrar, J; Giri, A; Karkey, A; Paris, DH; Thompson, CN; Thwaites, G, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thompson, CN | 4 |
| Karkey, A | 7 |
| Dongol, S | 7 |
| Arjyal, A | 8 |
| Wolbers, M | 5 |
| Darton, T | 1 |
| Farrar, JJ | 2 |
| Thwaites, GE | 3 |
| Dolecek, C | 9 |
| Basnyat, B | 9 |
| Baker, S | 7 |
| Bandyopadhyay, R | 1 |
| Balaji, V | 1 |
| Yadav, B | 2 |
| Jasmine, S | 1 |
| Sathyendra, S | 1 |
| Rupali, P | 1 |
| Koirala, S | 3 |
| Shilpakar, O | 1 |
| Shrestha, K | 3 |
| Shrestha, R | 1 |
| Shrestha, UM | 1 |
| Agrawal, K | 1 |
| Koirala, KD | 1 |
| Thapa, SD | 1 |
| Giri, A | 3 |
| Shakya, M | 2 |
| Pathak, KR | 2 |
| Campbell, J | 1 |
| Farrar, J | 4 |
| Näsström, E | 1 |
| Vu Thieu, NT | 1 |
| Voong Vinh, P | 2 |
| Ha Thanh, T | 2 |
| Johansson, A | 1 |
| Thwaites, G | 2 |
| Antti, H | 1 |
| Blacksell, SD | 1 |
| Paris, DH | 1 |
| Day, N | 1 |
| Nhan, HT | 1 |
| Joshi, N | 1 |
| Mahat, SP | 1 |
| Prajapati, SP | 1 |
| Adhikari, N | 1 |
| Thapa, R | 1 |
| Merson, L | 1 |
| Gajurel, D | 2 |
| Lamsal, K | 1 |
| Lamsal, D | 1 |
| Yadav, BK | 1 |
| Shah, G | 1 |
| Shrestha, P | 1 |
| Thieu, NTV | 1 |
| Thanh, DP | 1 |
| Pham Thanh, D | 1 |
| Ho Thi, N | 1 |
| Rabaa, MA | 1 |
| Holt, KE | 1 |
| Wong, V | 1 |
| Tran Vu Thieu, N | 1 |
| Pradhan, A | 1 |
| Shrestha, SK | 1 |
| Pickard, D | 1 |
| Parry, CM | 2 |
| Dougan, G | 1 |
| Beeching, NJ | 1 |
| Agrawaal, KK | 1 |
| Shakya, N | 1 |
| Sharma, M | 1 |
| Lama, S | 1 |
| Khatri, NS | 1 |
| Shrestha, U | 1 |
| Campbell, JI | 3 |
| Butler, T | 1 |
| Pandit, A | 1 |
| Day, JN | 1 |
| Paudyal, B | 1 |
| Dangol, S | 1 |
| Zimmerman, MD | 1 |
| Stepniewska, K | 2 |
| Tran, TP | 1 |
| Nguyen, NR | 1 |
| Le, TP | 1 |
| Ha, V | 1 |
| Phung, QT | 1 |
| Doan, CD | 1 |
| Nguyen, TB | 2 |
| Duong, TL | 1 |
| Luong, BH | 1 |
| Nguyen, TA | 1 |
| Pham, ND | 1 |
| Mai, NL | 1 |
| Phan, VB | 1 |
| Vo, AH | 1 |
| Nguyen, VM | 1 |
| Tran, TT | 1 |
| Tran, TC | 1 |
| Schultsz, C | 1 |
| Dunstan, SJ | 1 |
| To, SD | 1 |
| Nguyen, VV | 1 |
| Nguyen, VS | 1 |
| Nguyen, TC | 1 |
| Tran, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Parallel Group, Double Blinded, 1:1, Randomized Controlled Phase III Trial of Co-trimoxazole Versus Azithromycin for the Treatment of Undifferentiated Fever In Nepal[NCT02773407] | Phase 3 | 330 participants (Actual) | Interventional | 2016-05-23 | Completed | ||
| Randomized, Open-label, Superiority Trial of the Effectiveness of Gatifloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Enteric Fever.[NCT01421693] | Phase 4 | 300 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Azithromycin and Cefixime Combination Versus Azithromycin Alone for the Out-patient Treatment of Clinically Suspected or Confirmed Uncomplicated Typhoid Fever in South Asia; a Randomised Controlled Trial[NCT04349826] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2021-05-23 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gatifloxacin and Enteric Fever
| Article | Year |
|---|---|
Treatment of typhoid fever in the 21st century: promises and shortcomings.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Clinical Trials as Topic; Drug Resistance, Bacteri | 2011 |
7 trials available for gatifloxacin and Enteric Fever
| Article | Year |
|---|---|
Treatment Response in Enteric Fever in an Era of Increasing Antimicrobial Resistance: An Individual Patient Data Analysis of 2092 Participants Enrolled into 4 Randomized, Controlled Trials in Nepal.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Child; Drug Resistance, Multipl | 2017 |
Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial.
Topics: Adolescent; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gati | 2013 |
Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial.
Topics: Adolescent; Anti-Bacterial Agents; Ceftriaxone; Female; Fluoroquinolones; Gatifloxacin; Humans; Male | 2016 |
A novel ciprofloxacin-resistant subclade of H58 Salmonella Typhi is associated with fluoroquinolone treatment failure.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Ceftriaxone; Ciprofloxacin; Fluoroquinolones; Ga | 2016 |
Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Chloramphenicol; Feces; Fluoroquinolones | 2011 |
An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Cefixime; Ch | 2007 |
A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Child; Fluoroquinolones; Gatifloxacin; Humans; Microbial | 2008 |
A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Child; Fluoroquinolones; Gatifloxacin; Humans; Microbial | 2008 |
A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Child; Fluoroquinolones; Gatifloxacin; Humans; Microbial | 2008 |
A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Child; Fluoroquinolones; Gatifloxacin; Humans; Microbial | 2008 |
4 other studies available for gatifloxacin and Enteric Fever
| Article | Year |
|---|---|
Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Dr | 2018 |
Salmonella Typhi and Salmonella Paratyphi A elaborate distinct systemic metabolite signatures during enteric fever.
Topics: Area Under Curve; Bacterial Proteins; Biomarkers; Case-Control Studies; Fluoroquinolones; Gas Chroma | 2014 |
Undifferentiated febrile illness in Kathmandu, Nepal.
Topics: Anti-Bacterial Agents; Fever; Fluoroquinolones; Gatifloxacin; Humans; Nepal; Ofloxacin; Prospective | 2015 |
Outpatient treatment of patients with enteric fever.
Topics: Ambulatory Care; Anti-Infective Agents; Chloramphenicol; Fluoroquinolones; Gatifloxacin; Humans; Nep | 2011 |